

Implementing remote measurement technology in clinical pathways for depression, epilepsy and MS: Results from a large-scale survey of clinicians

AUTHORS: JA Andrews^{1,2} (jacob.andrews@nottingham.ac.uk), MP Craven^{1,3}, R Morriss^{1,2,5}, AR Lang⁴, J Jamnadas-Khoda^{1,2}, C Hollis^{1,2,5}, The RADAR-CNS consortium

1. NIHR MindTech MedTech Co-operative – IMH, Triumph Road, Nottingham, NG7 2TU **2. University of Nottingham -** School of Medicine, Division of Psychiatry and Applied Psychology | **3.**

University of Nottingham – Faculty of Engineering, Bioengineering, Research Group | 4. University of Nottingham – Faculty of Engineering, Human Factors Research Group | 5. NIHR Nottingham **Biomedical Research Centre** – University of Nottingham

Background

Remote Measurement Technology (RMT) uses the sensors and software found in wearable and mobile devices to record data on biological indicators, while additionally enabling collection of self-report data¹. These data can be used to gain insight into a person's physical and psychological health. However, little guidance is available to direct the use of RMT in healthcare settings and not much is known about how, or whether, data from these devices are currently being used in such settings².


The RADAR-CNS project seeks to explore the potential of RMT in epilepsy, depression and multiple sclerosis (MS)³. The present study seeks to explore the potential value of RMT for the management of these conditions, according to clinicians working in these specialisms.

Methods

Our primary objective was to understand if RMT interventions are **currently used** in clinical practice.

Our secondary objective was to understand where healthcare professionals believe there to be **potential** for the use of RMT in healthcare.

We conducted an online survey of clinicians working in the care of people with epilepsy, MS or depression. Recruitment to the survey was completed with assistance from the Clinical Research Network, also via social media



We asked respondents to indicate types of data that they would like their patients to measure using RMT. **Responses included:**

- Activity levels
- Alcohol intake
- Anxiety symptoms
- Appetite •
- Blood glucose
- Cognitive performance
- Diet/calorie intake
- EEG •
- Social media usage • Goals and achievement
- Heart rhythm
- Smartphone usage
- Interaction with others
- and epilepsy) • Walking speed

Medication usage and

• Micturition and bowel

• Mindfulness/relaxation

• Ability to swallow (for MS

movements (MS)

• Seizure frequency

(epilepsy)

adherence

• Mood

Conclusions

More than 50% of clinicians already use apps in their clinical practice, and over 75% of them report that their patients use smartphone apps or wearables for health-related purposes. Most respondents also indicate that data from patients' apps and wearables impact their work. Clinicians see promise in the use of RMT to help patients self-manage their conditions.

and contacts of the research team.

Ethical approval was granted by the University of Nottingham Research Ethics Committee, and approval was granted by the Health Research Authority for involvement of the Clinical Research Network.

There were 1009 responses to the survey, and after data cleaning 1006 were retained for analysis in Microsoft Excel.

Results


A total of 562 respondents (56%) reported using apps of some kind in their current clinical practice. Types of app reported to be used included guidelines apps (25% of respondents), calculation apps (11%), prescribing/dosing apps (19%) and communication apps (22%) (Figure 1).

A total of 780 respondents (78%) reported that their patients used smartphone apps or a wearable sensing device for health-related purposes, consisting of: weight management; sleep monitoring; activity monitoring; monitoring for a specific condition; monitoring mood; setting personal health goals; or another health-related use.

| Weight management | Sleep Monitoring | Activity Monitoring | Monitoring for a specific condition | Monitoring Mood | Setting personal health goals | Other uses |
|----------------------|---------------------|------------------------|---|--------------------|-------------------------------------|------------|
| | | | | | | |

Wearable sensing device Smartphone apps

Figure 1 | Percentages of respondents indicating they have experienced their patients bringing data to clinic that have been collected using smartphones or wearable devices for these purposes.



of patient health of their own health? making processes between yourself of patient health during consultation? and patients? state between state at consultations? consultation?

■ Definitely ■ Sometimes ■ Unsure ■ Hardly ■ Never

Figure 2 | Respondents' views of whether patients' data collected on apps and wearable devices affects different aspects of their clinical work. The majority of responses indicated that patients' RMT data were sometimes, or definitely useful for their clinical practice.

100%

It would therefore be timely for guidance to be produced on the use of RMT data, both for clinical practice and for patients to self-manage their condition. Our results also provide evidence of a need for pathways and software to manage data from patients' RMT.

Results indicated potential for RMT in all three conditions of interest, with variation in the particular data streams that would be of most use in each condition. Thus, patients and clinicians would benefit from condition-specific guidance as well as general guidance on principles of good practice with digital data.

References


¹Majumder, S., Monda, T., Deen, M.J. 2017. Wearable Sensors for Remote Health Monitoring. Sensors 17(1), 130. DOI: doi.org/10.3390/s17010130

²Vegesna, A., Tran, M., Angelaccio, M., Arcona, S. 2017 Remote Patient Monitoring via Non-invasive Digital Technologies: A Systematic Review. Telemedicine and e-Health 23(1). DOI: doi.org/10.1089/tmj.2016.0051

When asked whether data from their patients' devices impacted aspects of their practice, the majority of responses (average 62%) indicated that patients' data **sometimes or definitely impacted their work** (Figure 2).

The survey also showed that **clinicians would find RMT** data on sleep quality to be of use across all three of the central nervous disorders considered in this study (89% of respondents in epilepsy, 84% in MS and 96% in depression).

Analysis of responses revealed a largely positive attitude towards RMT, where 86% of respondents agreed or strongly agreed that 'technology is a good tool for helping patients to manage their condition themselves'.



■ MS ■ Depression Epilepsv

Figure 3 | Respondents' views on the usefulness of different types of data that could be collected using RMT, across three different central nervous system disorders. Percentages plotted here are results of subtracting percentage of 'no' responses from percentage of 'yes' responses in each data type and each condition. Thus bars above the x axis were more positively endorsed, while bars below the x axis were more negatively endorsed.

University of Nottingham UK | CHINA | MALAYSIA









³www.RADAR-CNS.org

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (RADAR-CNS grant No 115902) www.imi.europa.eu

www.radar-cns.org info@radar-cns.org



This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.